Goldman Sachs Group Inc Reiterates CHF 80 Price Target for Novartis AG (NOVN)

Novartis AG (VTX:NOVN) has been given a CHF 80 price target by research analysts at Goldman Sachs Group Inc in a research note issued on Saturday. The brokerage currently has a “neutral” rating on the stock.

Separately, JPMorgan Chase & Co. set a CHF 70 target price on Novartis AG and gave the company a “neutral” rating in a research note on Saturday.

Novartis AG (VTX:NOVN) traded up 0.13% during trading on Friday, reaching CHK 78.75. 5,144,966 shares of the company’s stock were exchanged. The stock’s 50-day moving average is CHK 76.13 and its 200-day moving average is CHK 73.94. Novartis AG has a 12-month low of CHK 67.40 and a 12-month high of CHK 82.80.

ILLEGAL ACTIVITY NOTICE: “Goldman Sachs Group Inc Reiterates CHF 80 Price Target for Novartis AG (NOVN)” was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.chaffeybreeze.com/2017/05/20/goldman-sachs-group-inc-reiterates-chf-80-price-target-for-novartis-ag-novn.html.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

12 Month Chart for VTX:NOVN

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply